A nursing infant consuming approximately 1000 mL of human milk per day would receive approximately 0.5 mg of cefepime per day.

If an allergic reaction to cefepime for injection occurs, discontinue the drug. https://www.webmd.com/drugs/2/drug-5296/cefepime-injection/details When cefepime for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. The overall clinical cure rate among the protocol-valid patients was 81% (51 cured/63 evaluable patients) in the cefepime plus metronidazole group and 66% (62/94) in the imipenem/cilastatin group.

Caution should be exercised when cefepime is administered to a nursing woman.Cefepime has not been studied for use during labor and delivery. There are insufficient clinical data to support the use of cefepime for injection in pediatric patients under 2 months of age or for the treatment of serious infections in the pediatric population where the suspected or proven pathogen is IN THOSE PATIENTS IN WHOM MENINGEAL SEEDING FROM A DISTANT INFECTION SITE OR IN WHOM MENINGITIS IS SUSPECTED OR DOCUMENTED, AN ALTERNATE AGENT WITH DEMONSTRATED CLINICAL EFFICACY IN THIS SETTING SHOULD BE USED.Of the more than 6400 adults treated with cefepime for injection in clinical studies, 35% were 65 years or older while 16% were 75 years or older. (See Concentrations of cefepime achieved in specific tissues and body fluids are listed in Table 3.Data suggest that cefepime does cross the inflamed blood-brain barrier. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix™) be used.No animal carcinogenicity studies have been conducted with cefepime. Cefepime has a broad spectrum of Cefepime has been shown to be active against most isolates of the following microorganisms, both NOTE: Cefepime is inactive against many isolates of When available, the clinical microbiology laboratory should provide the results of Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). The MICs should be determined using a standardized test methodQuantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. Treatment should only be given if clearly indicated.The safety and effectiveness of cefepime in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and as empiric therapy for febrile neutropenic patients have been established in the age groups 2 months up to 16 years. Repeated evaluation of the patient’s condition is essential. The chemical name is 1-[[(6R,7R)-7-[2-(2-amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium chloride, 7Cefepime hydrochloride is a white to pale yellow powder. The recommended initial dose of cefepime for injection should be the same as in patients with normal renal function except in patients undergoing hemodialysis. If this occurs, patients should contact their physician as soon as possible.Patients should be advised of neurological adverse events that could occur with cefepime for injection use. IF PARTICULATE MATTER IS EVIDENT IN RECONSTITUTED FLUIDS, THE DRUG SOLUTION SHOULD BE DISCARDED.IN THE DRY STATE STORE AT 20° TO 25°C (68° TO 77°F) [SEE USP CONTROLLED ROOM TEMPERATURE].